Imaging currently play an important role in routine clinical care and clinical trials in triaging patients to appropriate management and in monitoring patients on therapy. In terms of treatment assessment it is essential for imaging markers to be consistent, reproducible and validated. Standardized response assessment based on morphological change, such as RECIST 1.1 is well established in the clinical trial setting although its limitations for therapies beyond standard chemotherapy are recognised e.g. immunotherapy, and for which alternative response criteria have been proposed. Computed tomography (CT) remains that most commonly performed imaging modality due to its high spatial resolution and its cost-effectiveness, but positron emission tomography (PET) and magnetic resonance imaging (MRI) have advantages in their capability to image beyond morphology. Measurement of glucose metabolism, cell proliferation, hypoxia, and vascularisation is now possible in clinical practice as well as quantification of their spatial variation, providing an imaging phenotype that is likely to be more beneficial than simple biomarkers e.g. size in predicting individual patient response to therapy. These imaging methods can also be integrated with genomic and pathological data allowing a comprehensive approach to address the clinical need towards individualisation of therapy in the future. In personalized medicine, early prediction of pathologic complete response for locally advanced rectal cancer (LARC) patients is essential to tailor treatment. The standard treatment for LARC patients consists of preoperative chemoradiotherapy (CRT) followed by surgery, with a complete response being observed in 15-30% of the patients after the neo-adjuvant treatment. Overtreatment of complete responders could be avoided if an accurate prediction of pCR is available, by selecting a wait-and-see policy instead of surgery after CRT, and thereby reducing treatment related complications. Further treatment strategies based on the prediction of pCR include a radiotherapy boost after CRT for patients with good response to achieve a higher complete response rate, and additional chemotherapy after initial CRT for the worst responding patients. In recent years, [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging has been increasingly used for decision support, treatment planning and response monitoring during radiotherapy. Radiomics (www.radiomics.org; animation: http://youtu.be/Tq980GEVP0Y) is a high throughput approach to extract and mine a large number of quantitative features from medical images, characterizing tumor image intensity, shape and texture. The core hypothesis of radiomics is that it can provide valuable diagnostic, prognostic or predictive information. FDG-PET radiomics may therefore facilitate early and accurate prediction of tumor response to treatment to identify LARC patients eligible for a wait and see or organ preserving approach, or patients who may benefit from treatment intensification. This presentation will focus on the methodology of, and technical challenges in, the development and validation of a predictive PET radiomic model for pCR in LARC patients, illustrated with recent data.
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MRI imaging of irradiated liver tissue for in vivo verification in particle therapy C. Richter In vivo treatment verification is highly desirable, especially but not only in particle therapy where uncertainties in the particle range can compromise the physical advantage of this treatment modality. Existing measurement techniques for range measurements exploit physical effects, in particular secondary radiation that is produced by the proton beam, for example through activation of positron emitters, or prompt gamma radiation. Also biological effects caused by the irradiation can be used for in vivo treatment verification, if a functional imaging method is available to visualize the effect. One prominent example for biology-driven range verification is an irradiation-induced change in contrast-enhanced MRI of the liver. A strong systematic decrease in uptake of the hepatobiliary-directed contrast agent Gd-EOB-DTPA has been shown in irradiated healthy liver tissue 6-9 weeks after irradiation [1-3] using different treatment modalities (brachytherapy, stereotactic body radiation therapy with photons and protons). The underlying mechanism seems to be based on a pro-inflammatory reaction of the irradiated liver tissue resulting in a downregulation of the Gd-EOB-DTPA uptake transporters and an upregulation of the respective excretion transporters [4] . In a prospective clinical study, carried out at Massachusetts General Hospital in Boston (USA), we investigated whether MRI of the liver can be used for in vivo dosimetric verification already during the course of hypo-fractionated proton therapy of liver metastases (5 fractions within 2 weeks). In contrast to the previously found late changes weeks after the end of treatment that were seen in all patients, for the early Gd-EOB-DTPA enhanced MR imaging large inter-patient variations were found. For 10 patients, strong or moderate signal changes were detected for 2 and 3 patients, respectively. For 5 patients no dose-correlated early signal change was found at all. This qualitative scoring was consistent with a quantitative voxelwise dose to signal change correlation. The analysis of additional parameters that could potentially explain inter-patient variations (e.g. dose delivered at time of MRI scans, several timing parameters, liver function parameters and circulating biomarkers of inflammation determined from blood samples taken before and during treatment) revealed no clear correlation or trend with the strength of the signal decrease. Hence, irradiation-induced effects in the liver can be detected with Gd-EOB-DTPA enhanced MRI within a few days after proton irradiation in a subgroup of patients. As all patients possessed a signal decrease in late follow up scans, only the early dynamics of the liver response is influenced by these inter-patient variations. The reason for these large variations in early response is not yet fully understood and needs further investigation. This presentation will cover a brief overview of biological effects used for treatment verification and will then focus on the irradiation-induced signal change in Gd-EOB-DTPA enhanced MRI of the liver. The hypothesis for the biological mechanism, the available data for late and early MRI signal changes will be presented and open questions will be discussed. The statements that will be made highlighting the strong position we are already in when using all currently available advanced image-guidance strategies are used are the following: -If there is a necessity for on line MR-guidance, there is a general necessity for broad use of advanced image guidance strategies, particularly as successful screening programs such as those for lung cancer and potentially even pancreatic cancer are established, as this potentially leads to more localized disease being treated.
-Several such strategies are now available but are underutilized, typically for lack of funding or perceived complexity. Recent developments such as FFF-delivery and fast collimators have, however, shortened a lot of treatments and thus rendered advanced imaging strategies more feasible. Considerable expertise is needed, as it is mandatory also for MR-guidance.
-MR-guidance can be and has already been more easily applied to brachytherapy, a highly effective form of local therapy where technically applicable.
-Continuous 2D-tracking based on fiducials placed in minimally invasive procedures has entered the clinical routine for the ablation of small lesions without complex interference of OARs.
-3D-imaging with CBCT, particularly in conjunction with breathhold strategies, still has considerable potential. Accuracies in the range of 3mm can be consistently achieved across treatment targets, in deep inspiration breathhold typically with very favorable dose distributions and straightforward dose accumulation. 4D-approaches are available, ultrafast "snapshot" volume imaging is ready to be deployed clinically.
-Ultrasound, where applicable, allows not only for positioning but for tracking in 2D and 3D.
-Surface scanning may simultaneously provide patient surveillance and gating signals during a therapy session. -Noncoplanar treatment strategies and high-LET radiation may have further potential to improve clinical results independent of imaging strategy and are currently not possible in conjunction with in-room MR-guidance. The statements suggesting that in-room MRI guidance will add significantly to the current armamentarium comprise the following: -Cancer is primarily a soft tissue disease. MRI offers unparalleled soft tissue contrast imaging across a wide range of cancer types and locations. In-room MRI guidance for cancer radiotherapy combines exquisite soft tissue imaging of the cancer and surrounding healthy structures with precision radiotherapy to optimally target the cancer and spare healthy tissues, affecting quality of life, cancer outcomes and reducing the health and economic burden of managing treatment-related side effects.
-This ability to simultaneously image and target the cancer with radiotherapy is intuitive to patients and the treatment team alike. Indeed, the image quality of MRI-guidance is so high that a commercial online adaptive radiotherapy solution is only available with these systems.
-Cancer physiology is heterogeneous and changes with time. MRI is the only in-room physiological targeting system for cancer radiotherapy. An example, tumor hypoxia, is a strong negative prognostic indicator of survival across a wide range of cancer sites, and the tumor hypoxic status changes over the time period of a single treatment. The ability to selectively image and target the most aggressive and resistant parts of the cancer opens up a new window to dramatically change cancer outcomes.
-In addition to in-room MRI-guidance offering an improved treatment across a range of cancer sites, this new device also opens up the opportunity to explore the treatment of nononcologic diseases. An example is atrial fibrillation, a disease suffered by 6 million Europeans, with many of these patients treated in an invasive, long, expensive procedure. MRI-guided radiotherapy offers a non-invasive, short and cost-effective treatment of atrial fibrillation. This treatment is enabled by using MRI to solve the challenging problem of imaging and targeting small volumes affected by both respiratory and cardiac motion, a problem too difficult for other in-room imaging systems.
-The improved outcomes and applications observed from inroom MRI-guided radiotherapy will affect patient referral patterns and policy guidelines to increase the global radiotherapy need, benefiting the radiation oncology and global communities. Advances in radiotherapy delivery have been due to improved technique and image guidance. In contrary to the "one size fits it all" paradigm, personalized medicine trys to incorporate all available imaging information in order to optimally delineate the target volume. It will be highlighted, in how far molecular imaging such as PET has become a cornerstone for certain types of cancer and how PET information may be integrated into target delineation. Furthermore, it will be discussed in how far there is a role for a biological target volume (BTV) and how appropriate margins can be chosen; new tracers beyond FDG are discussed. The meaning of MRI and its applications as well as available pitfalls will be presented employing an example of a brain tumor treatment.
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General recontouring with deformal registration X. Geets 
UCL -MIRO Lab -IREC, Radiation Oncology, Brussels, Belgium
Significant patient anatomy changes may occur during the course of radiotherapy, more particularly for head and neck, pelvic and lung tumours. These modifications may degrade the plan quality over time, and hence require treatment adaptation based on the anatomy depicted from images of the treatment day. Any comprehensive adaptive solution will necessarily require automatic tools that, first, depict patients who actually need adaptation (dose recomputation on daily image and clinical indicators of plan quality), and then assist the radiation oncologist/therapist in the labour-intensive task of target volumes and organs at risk recontouring. Ultimately, this approach should allow treatment plan re-optimization if required, without unmanageable additional workload in reallife clinical routine. In this framework, deformable image registration allows the alignment of datasets in a non-linear way, providing a voxel-
